Phase 1/2, Open-Label, Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ701 in Adults with ENPP1 Deficiency

被引：0
|
作者：
Sabbagh, Yves [1 ]
Wermers, Robert [2 ]
Fuhr, Rainard [3 ]
Schnabel, Dirk [4 ]
Arnason, Terra [5 ]
Besancon, Alix [6 ]
Cizman, Borut [1 ]
Wenkert, Deborah [7 ]
Gunter, Kurt [1 ]
机构：
[1] Inozyme Pharma, Boston, MA USA
[2] Mayo Clin, Rochester, MN USA
[3] Parexel Int GmbH, Early Phase Clin Unit, Berlin, Germany
[4] Charite, Ctr Chron Sick Children, Pediat Endocrinol, Berlin, Germany
[5] Univ Saskatchewan, Div Endocrinol, Saskatoon, SK, Canada
[6] Hop Univ Necker Enfants Malades, Endocrinodiabetol Pediat, Paris, France
[7] Wenkert & Young LLC, Thousand Oaks, CA USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SUN-504
引用
收藏
页码：376 / 377
页数：2
相关论文
共 50 条
  • [21] A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma
    Beckermann, Kathryn E.
    Patnaik, Amita
    Winer, Ira
    Tan, Winston
    Bashir, Babar
    Kyriakopoulos, Christos E.
    Sweis, Randy F.
    Chamberlain, Marc
    Rini, Brian I.
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (02) : 179 - 184
  • [22] A phase 1 randomized open-label clinical study to evaluate the safety CrossMark and tolerability of a novel recombinant hepatitis E vaccine
    Cao, Yu-Feng
    Tao, Hong
    Hu, Yue-Mei
    Shi, Cheng-Bo
    Wu, Xing
    Liang, Qi
    Chi, Chun-Ping
    Li, Li
    Liang, Zheng-Lun
    Meng, Ji-Hong
    Zhu, Feng-Cai
    Liu, Zhao-Hui
    Wang, Xin-Ping
    VACCINE, 2017, 35 (37) : 5073 - 5080
  • [23] A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma
    Kathryn E. Beckermann
    Amita Patnaik
    Ira Winer
    Winston Tan
    Babar Bashir
    Christos E. Kyriakopoulos
    Randy F. Sweis
    Marc Chamberlain
    Brian I. Rini
    Investigational New Drugs, 2024, 42 : 179 - 184
  • [24] A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
    Trivedi, Ashit
    Mather, Omar
    Vega, Silvia
    Hutton, Shauna
    Hellawell, Jennifer
    Lee, Edward
    DRUGS IN R&D, 2022, 22 (02) : 141 - 146
  • [25] A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
    Ashit Trivedi
    Omar Mather
    Silvia Vega
    Shauna Hutton
    Jennifer Hellawell
    Edward Lee
    Drugs in R&D, 2022, 22 : 141 - 146
  • [26] ASCENDING MULTIPLE-DOSE STUDY WITH PONESIMOD, A SELECTIVE SIP1 RECEPTOR AGONIST: TOLERABILITY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS
    Brossard, P.
    Maatouk, H.
    Halabi, A.
    Dingemanse, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S93 - S93
  • [27] Tolerability and safety of facilitated subcutaneous immunoglobulin 20% in healthy adults: a phase 1 open-label study
    Nagy, Andras
    Khaskhely, Noor
    Duff, Kimberly
    Bauer, Alexander
    Okonneh, Fred
    Rondon, Juan Carlos
    Yel, Leman
    Li, Zhaoyang
    CLINICAL IMMUNOLOGY, 2023, 250 : 36 - 36
  • [28] An Open-Label Phase 2a Study to Evaluate the Safety and Tolerability of Perampanel in Cervical Dystonia
    Fox, Susan H.
    Swan, Matthew
    Jinnah, Hyder A.
    Freitas, Maria E. T.
    Oliveira, Lais M.
    Al-Shorafat, Duha
    Fernandez, Hubert H.
    Kompoliti, Katie
    Comella, Cynthia
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2021, 8 (05): : 743 - 749
  • [29] Phase 1 open-label study evaluating pharmacokinetics, safety, and tolerability of linifanib in Japanese patients with solid tumors
    Tamura, Tomohide
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Asahina, Hajime
    Shibata, Takashi
    Goto, Yasushi
    Tanioka, Maki
    Tamura, Yosuke
    Seki, Yoshitaka
    Chiu, Yi-Lin
    Gupta, Neeraj
    Carlson, Dawn
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [30] Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study
    Watanabe, Eizo
    Nishida, Osamu
    Kakihana, Yasuyuki
    Odani, Motoi
    Okamura, Tatsuaki
    Harada, Tomohiro
    Oda, Shigeto
    SHOCK, 2020, 53 (06): : 686 - 694
12345